GPT Healthcare Ltd

GPT Healthcare Ltd has announced the closure of its trading window for designated persons and their immediate relatives, effective October 1, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The window will remain shut until 48 hours after the declaration of the company's Un-Audited Financial Results for the second quarter and half-year ending September 30, 2026. The exact date of the board meeting to approve these results will be communicated later. Designated individuals are advised against trading in the company's securities during this period. The information is also available on the company's website.

GPT Healthcare Limited reported its unaudited financial results for the first quarter ended June 30, 2026. Total income for Q1FY27 stood at ₹128.2 crore, an 18% year-on-year increase from ₹108.7 crore in Q1FY26. EBITDA grew by 38.5% YoY to ₹26.2 crore, with an improved EBITDA margin of 20.4%. Profit After Tax (PAT) surged by 65.7% YoY to ₹12.7 crore, resulting in a PAT margin of 9.9%. Key operational highlights include steady improvement in occupancy rates to 58.07% (excluding Raipur), over 700 renal transplants at ILS Dum Dum, and the launch of a Robotic Knee Surgery program at ILS Howrah. ILS Raipur received its liver transplant license and is expected to break even by Q3 FY27. The company is also finalizing its seventh hospital, aiming to increase network capacity to over 1,000 beds.

GPT Healthcare Limited announced its un-audited financial results for the first quarter ended June 30, 2026. The Board of Directors approved and took on record the results during their meeting held on August 3, 2026. As the company has no subsidiaries or associate entities, consolidated financial results were not required. The results were accompanied by a Limited Review Report from the statutory auditors, S.R. Batliboi & Co. LLP.

GPT Healthcare's standalone revenue from operations rose 17.8% YoY to ₹126.20 Cr (Q1FY26: ₹107.11 Cr), while PAT climbed 65.7% YoY to ₹12.73 Cr (Q1FY26: ₹7.68 Cr) on basic EPS of ₹1.55 versus ₹0.94. Sequentially revenue was flat (-0.1% QoQ vs ₹126.37 Cr in Q4FY26), but PAT fell 12.6% QoQ from ₹14.57 Cr — a tax-driven dip, not an operating one: PBT actually grew 8.2% QoQ to ₹17.16 Cr, but Q4FY26's effective tax rate was an unusually low ~8.2% (helped by a ~₹3.50 Cr deferred-tax credit) against this quarter's normalized ~25.8% rate. Operating margin (EBITDA/revenue, computed as PBT less other income plus depreciation and finance costs, over revenue) expanded to 19.16% from 16.21% a year ago and 18.49% last quarter, pointing to genuine operating leverage as cost lines (materials, employee expense) grew slower than revenue. Net margin (PAT/total income) improved YoY to 9.93% from 7.07%, though it read lower than Q4FY26's 11.38% purely because of the tax-base effect described above. Management's FY27 guidance (from the Q4FY26 concall) called for 15% YoY revenue growth, ~8% ARPOB growth, and a step-up to ~20.2% EBITDA margin for the full year, alongside Raipur hospital reaching monthly breakeven by Q3FY27 (~30% occupancy by year-end) and a ~150-bed Jamshedpur addition by Q4FY27. Q1's 17.8% YoY revenue growth already runs ahead of the 15% annual guidance pace, and the 19.16% OPM is progressing toward, though still short of, the 20.2% full-year target — consistent with management's own outlook rather than contradicting it. The filing discloses only one reportable segment (healthcare services in India, Note 3), so hospital-level Raipur/Jamshedpur progress cannot be independently verified from these numbers. No management press release was available in the context to cross-check messaging, and no broker/consensus estimates for this quarter could be located in a web search, so the print cannot be benchmarked against street numbers this quarter. Corporate developments this quarter were administrative — the board approved results at today's meeting, following the trading-window closure on June 27 and the July 9 dispatch of the AGM notice along with a ₹1.50/share final FY26 dividend — none of which bear on the operating print.

GPT Healthcare Ltd has announced that its Board of Directors will convene on August 3, 2026. The primary agenda item is to consider and approve the Unaudited Financial Results for the first quarter ended June 30, 2026, along with the Statutory Auditor's Limited Review Report. The trading window for company securities will remain closed until August 5, 2026, to prevent insider trading, as per the company's code of conduct. This information is also available on the company's website.

GPT Healthcare Ltd has dispatched letters to shareholders whose email addresses are not registered, providing a web-link to access the complete Annual Report for FY 2025-26 and the Notice for the 37th Annual General Meeting (AGM). The AGM is scheduled for August 8, 2026, via Video Conferencing. The company is also providing details on dividend payment and e-voting. The information is available on the company's website and the Registrar & Transfer Agent's portal.

GPT Healthcare Ltd has announced its 37th Annual General Meeting (AGM) will be held on August 6, 2026, at 3:00 PM IST via Video Conferencing. The company proposes a final dividend of ₹1.50 (15%) per equity share for FY2025-26, subject to shareholder approval. The record date for this dividend is July 30, 2026. The AGM agenda includes adopting financial statements, confirming interim and declaring final dividends, re-appointing a director, and ratifying the remuneration of cost auditors. Additionally, the AGM will consider an increase in remuneration for Dr. Mridul Tantia. E-voting will be open from August 3 to August 5, 2026.

GPT Healthcare Limited has announced its 37th Annual General Meeting (AGM) for the Financial Year 2025-26. The AGM is scheduled to be held on Thursday, August 6, 2026, at 3:00 PM IST, conducted via Video Conferencing and Other Audio-Visual Means (VC/OAVM). The company has enclosed its 37th Annual Report, including the Notice of AGM and other statutory reports for FY 2025-26. This report is being disseminated electronically to members with registered email addresses and a web-link is provided for others. The Annual Report is also available on the company's website, www.ilshospitals.com. The filing also includes a tribute to the founder, Late Dwarika Prasad Tantia, highlighting his vision and values.

GPT Healthcare Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's code of conduct. The window will remain shut from July 1, 2026, until 48 hours after the declaration of the unaudited financial results for the first quarter ending June 30, 2026. The exact date of the board meeting to approve these results will be communicated later. Designated individuals are advised against trading in the company's securities during this period. The information is also available on the company's website.

GPT Healthcare Ltd has launched its Second 100 Days Campaign, "Saksham Niveshak," in line with the IEPFA's directive. This initiative aims to help shareholders claim unpaid/unclaimed dividends and complete KYC formalities to prevent their transfer to the IEPF. The company has dispatched letters to affected shareholders and provided details on its website. Shareholders are urged to update KYC, claim dividends, and submit necessary forms (ISR-1, ISR-2, ISR-3, SH-13, SH-14) to the Registrar and Transfer Agent, MUFG Intime India Private Limited, or their respective depositories to ensure timely credit of dividends and avoid transfer of shares and dividends to the IEPF.